Skip to main content

COVID 19

COVID-19 services

  • Do you need assays to test immune responses to vaccines or novel therapeutics?
  • Are you looking for new drug targets?
  • Do you require safety and efficacy testing for COVID-19 vaccines under development?
  • Do you require testing of your immunomodulatory inhibitors for SARS-CoV-2?
  • Do you want to test reprositioned drugs ??

If this is familiar to you then Alcyomics can be your partner to expedite therapeutic development and de-risk clinical trials.

 

Background:

The incubation period of SARS-CoV-2 is 3-7 days. 80% of infections are classified as mild or asymptomatic, 15% are severe and require oxygen and 5% of cases are critical requiring ventilation. The virus uses the protein ACE2 as a host cell receptor to infect the human airway epithelia. The spike (S) and nucleocapsid (N) proteins have been identified as the most immunogenic expressed proteins during infection.

Specific T cell responses against SARS-CoV-2 is important for recognition and killing of infected cells in the lung. The ‘cytokine storm’ produced in SARS-CoV-2 susceptible individuals is a severe systemic inflammatory response releasing pro-inflammatory cytokines (such as IFN-α, IFN-γ, IL-1β, IL-6, etc.) and chemokines (such as CCl1, CCL2, CCL5, CXL8, CXL9, CXL10, etc.). Differences in the cytokine profile have been observed when comparing severe versus mild infected patients.

 

Rationale for Alcyomics service provision: 

  • Understanding the immune response to SARS-CoV-2 is critical for the evaluation of vaccines and clinical management of patients.
  • The ‘cytokine storm’ that occurs in the most susceptible individuals is a serious systemic inflammatory response releasing several pro-inflammatory cytokines and chemokines.
  • A better understanding of this in patients is necessary for the development of novel therapeutics, clinical management and successful clinical trials.

 

Evaluating immune responses to vaccines and novel therapeutics:

We have further developed our DC/T cell assay for the assessment of vaccine peptides. Here, we use fresh blood from an individual and allow the test article to present itself to the DCs. If the test article causes activation of the immune system, this can subsequently be determined by T cell proliferation readout and multiplex cytokine and chemokine analysis.

Our readouts of cytokine/chemokine profiles, T cell proliferation, Tc/Th subset profiles and mRNA expression analysis on activated DCs can provide you with valuable information regarding how immunogenic peptides are activating the human immune system and the mode of action.

 

Are you looking for new drug targets or mode of action of reprositioned drugs ?

Using our in-house screening tests Alcyomics are able to:

  • Detect immune responses to SARS-CoV-2 antigenic spike and nucleocapsid peptides and assess cytokine and chemokine release.
  • Tc/Th ratios and determine immune response using a range of HLA phenotypes.
  • RNA-Seq and mRNA expression analysis will be used to identify novel drug targets.
  • New or repositioned  drugs can be tested to see their effect on SARS-COV2 immune responses

 

We also aim to use our proprietary technology to test SARS-CoV-2 peptides identified from spike and nucleocapsid immunogenic proteins associated with HLA class I and class II epitopes to discover novel drug targets. This is valuable information for drug discovery efforts to design therapeutic strategies to modulate the immune response/ vaccine development. For more information contact us 

Safety and efficacy testing for COVID-19 vaccines under development:

Testing your immunomodulatory inhibitors to SARS-CoV-2:

We can use our immunomodulatory/immune inhibition Skimune® assay as well as inhibiting T cell responses in the assessment of drugs. Contact us for more information on this assay.

 

Summary: Working with Alcyomics:

  • Do you need assays to test immune responses to vaccines or novel therapeutics?

Our patented Skimune® platform is suitable for the testing of immune responses to vaccines and novel therapeutics.

 

  • Are you looking for new drug targets?

Using our Skimune® platform and SARS-CoV-2 S and N proteins we can induce immune responses and investigate the pathways and networks involved to identify drug targets, using RNA-Seq, mRNA expression analysis, multiplex cytokine/chemokine profiles and investigate mode of action.

 

  • Do you require safety and efficacy testing for COVID-19 vaccines under development?

Using anti-viral T cell specific assays and our Skimune® platform we can demonstrate safety and efficacy of anti-viral vaccines.

 

  • Do you require testing of your immunomodulatory inhibitors for SARS-CoV-2?
  • Do you want to test new or repositioned  drugs to see their effect on SARS-COV2 immune response??s

To assess the efficacy of your drugs to suppress the ‘cytokine storm’, Alcyomics can use our immunomodulatory/immune inhibition Skimune® model as well as inhibiting T cell responses in the assessment of drugs.

If you would like more information on how these assays can help your business, please contact us.

  • This form collects your name and email so what we can add your to our newsletter list and send you relevant updates via email. Read our privacy policy for details on how we manage your data.